STING1 and neoplasm: STING-NPs have been shown to enhance cGAMP activity by multiple orders of magnitude while also improving pharmacokinetic properties of intravenously administered cGAMP, resulting in enhanced STING activation at solid tumor sites with a concomitant inhibition of tumor growth in multiple subcutaneous tumor models (36, 37).